ASBP Research | Milton Maxwell

ASBP

Aspire Biopharma Holdings, Inc.

0.1043

-0.0031-2.89%

Dec 16, 4:00:02 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

14.44M

P/E (TTM)

Basic EPS (TTM)

-0.64

Dividend Yield

Recent Filings

8-K

Secures $2M OID debentures

1/30/26Jan 30, 2026

Aspire Biopharma secured $2M via 8% OID debentures (principal $2.17M) maturing April 23, 2026, or sooner upon $8M financing, issued non-convertible with prepayment option. Purchasers got 790,000 incentive shares. Funds target debt payoff and working capital, yet short timeline pressures liquidity.

8-K

Confirms 4.89M-share incentive plan

1/15/26Jan 15, 2026

Aspire Biopharma confirmed terms of its 2024 Stock Incentive Plan on January 8, 2026, setting the share limit at 4,890,000 after stockholder approval in February 2025. Board approved RSU and option award forms for executives, directors, and employees, tying vesting to continued service. Equity pool now active. Plan aligns talent with shareholders.

8-K

Director resigns immediately

1/13/26Jan 13, 2026

Aspire Biopharma Holdings director Surendra Ajjarapu resigned effective January 7, 2026. His departure stems from personal reasons, with no disagreements cited involving the company, board, or management. Board now has one fewer director.

8-K

Debt-for-equity swap announced

1/6/26Jan 6, 2026

Aspire Biopharma entered Exchange Agreements on January 1, 2026, with PowerUp sponsors to swap ~$1.75M debt—stemming from 2024 subscription deals—for common stock. Holders control timing via up to four notices by January 31, 2026, at closing price minus $0.01; shares issue freely tradeable. Debt eases balance sheet strain, yet dilution looms large. Holders snag 25% repayment option on financings over $3M.

10-Q

Q3 FY2025 results

11/14/25Nov 14, 2025

Aspire Biopharma notched its first revenue of $1,941 in Q3 FY2025 ended September 30, up from zero a year earlier, yielding $884 gross profit while operating expenses swelled to $1.1M from $215K on higher R&D and marketing. Net loss hit $1.85M, versus $216K prior year, as $1.48M interest expense from convertible notes outpaced $775K derivative gains. Cash sits at $1.95M after $4M ops burn, backed by $13.9M liabilities including $4.7M convertibles; financing propped $5.9M inflows. Reverse recap closed February 2025. Nasdaq delisting risk looms from low market value.

About

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

CEO

Mr. Kraig T. Higginson

IPO

4/11/2022

Website

https://aspirebiolabs.com

Sector

Healthcare

Industry

Biotechnology